Last reviewed · How we verify

Miglani, Anjali — Portfolio Competitive Intelligence Brief

Miglani, Anjali pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Lappa Arctium Lappa Arctium marketed
Zingiber officinalis Zingiber officinalis marketed Herbal/botanical extract Gastroenterology, Rheumatology, General wellness

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ain Shams University · 1 shared drug class
  2. Birjand University of Medical Sciences · 1 shared drug class
  3. National Center for Complementary and Integrative Health (NCCIH) · 1 shared drug class
  4. Tatyasaheb Kore Dental College · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Miglani, Anjali:

Cite this brief

Drug Landscape (2026). Miglani, Anjali — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/miglani-anjali. Accessed 2026-05-16.

Related